http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2025, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 08 Dec 2025 07:11:41 -0500 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Analyst+Comments/KeyBanc+on+Life+Sciences+Tools+%26+Services%3A+%27We+Highlight+Our+Favored+2026+%22Tools%22+Stocks%27/25709383.html <p>KeyBanc analyst Paul Knight highlights favorite 2026 Life Sciences Tools & Services ideas from large to microcap.</p><p>The analyst commented: "Relative to a mostly predictable 20+ years in Life Science Technology, the last three have been harrowing. Destocking and lower funding weighed on 2023-2024 revenue and a hostile DC environment of NIH budget cuts, tariffs, and drug pricing shook investor confidence in 2025. However, with policy issues dissipating, improved biopharma spend was evident with 3Q25 earnings (best in ~2 years) and large-caps DHR and TMO are leading a share price recovery. Data points in our LabBook signal more momentum in 2026, http://www.streetinsider.com/Analyst+Comments/KeyBanc+on+Life+Sciences+Tools+%26+Services%3A+%27We+Highlight+Our+Favored+2026+%22Tools%22+Stocks%27/25709383.html Mon, 08 Dec 2025 07:11:41 -0500 AVTR BDX BLFS CYRX DHR PPD RGEN RPID STVN TMO WAT WST XGN http://www.streetinsider.com/Analyst+Comments/KeyBanc+on+Life+Sciences+Tools+%26+Services%3A+%27We+Highlight+Our+Favored+2026+%22Tools%22+Stocks%27/25709383.html <p>KeyBanc analyst Paul Knight highlights favorite 2026 Life Sciences Tools & Services ideas from large to microcap.</p><p>The analyst commented: "Relative to a mostly predictable 20+ years in Life Science Technology, the last three have been harrowing. Destocking and lower funding weighed on 2023-2024 revenue and a hostile DC environment of NIH budget cuts, tariffs, and drug pricing shook investor confidence in 2025. However, with policy issues dissipating, improved biopharma spend was evident with 3Q25 earnings (best in ~2 years) and large-caps DHR and TMO are leading a share price recovery. Data points in our LabBook signal more momentum in 2026, http://www.streetinsider.com/Analyst+Comments/KeyBanc+on+Life+Sciences+Tools+%26+Services%3A+%27We+Highlight+Our+Favored+2026+%22Tools%22+Stocks%27/25709383.html Mon, 08 Dec 2025 07:11:41 -0500 AVTR BDX BLFS CYRX DHR PPD RGEN RPID STVN TMO WAT WST XGN http://www.streetinsider.com/Analyst+Comments/KeyBanc+on+Life+Sciences+Tools+%26+Services%3A+%27We+Highlight+Our+Favored+2026+%22Tools%22+Stocks%27/25709383.html <p>KeyBanc analyst Paul Knight highlights favorite 2026 Life Sciences Tools & Services ideas from large to microcap.</p><p>The analyst commented: "Relative to a mostly predictable 20+ years in Life Science Technology, the last three have been harrowing. Destocking and lower funding weighed on 2023-2024 revenue and a hostile DC environment of NIH budget cuts, tariffs, and drug pricing shook investor confidence in 2025. However, with policy issues dissipating, improved biopharma spend was evident with 3Q25 earnings (best in ~2 years) and large-caps DHR and TMO are leading a share price recovery. Data points in our LabBook signal more momentum in 2026, http://www.streetinsider.com/Analyst+Comments/KeyBanc+on+Life+Sciences+Tools+%26+Services%3A+%27We+Highlight+Our+Favored+2026+%22Tools%22+Stocks%27/25709383.html Mon, 08 Dec 2025 07:11:41 -0500 AVTR BDX BLFS CYRX DHR PPD RGEN RPID STVN TMO WAT WST XGN http://www.streetinsider.com/Analyst+Comments/KeyBanc+on+Life+Sciences+Tools+%26+Services%3A+%27We+Highlight+Our+Favored+2026+%22Tools%22+Stocks%27/25709383.html <p>KeyBanc analyst Paul Knight highlights favorite 2026 Life Sciences Tools & Services ideas from large to microcap.</p><p>The analyst commented: "Relative to a mostly predictable 20+ years in Life Science Technology, the last three have been harrowing. Destocking and lower funding weighed on 2023-2024 revenue and a hostile DC environment of NIH budget cuts, tariffs, and drug pricing shook investor confidence in 2025. However, with policy issues dissipating, improved biopharma spend was evident with 3Q25 earnings (best in ~2 years) and large-caps DHR and TMO are leading a share price recovery. Data points in our LabBook signal more momentum in 2026, http://www.streetinsider.com/Analyst+Comments/KeyBanc+on+Life+Sciences+Tools+%26+Services%3A+%27We+Highlight+Our+Favored+2026+%22Tools%22+Stocks%27/25709383.html Mon, 08 Dec 2025 07:11:41 -0500 AVTR BDX BLFS CYRX DHR PPD RGEN RPID STVN TMO WAT WST XGN http://www.streetinsider.com/Analyst+Comments/KeyBanc+on+Life+Sciences+Tools+%26+Services%3A+%27We+Highlight+Our+Favored+2026+%22Tools%22+Stocks%27/25709383.html <p>KeyBanc analyst Paul Knight highlights favorite 2026 Life Sciences Tools & Services ideas from large to microcap.</p><p>The analyst commented: "Relative to a mostly predictable 20+ years in Life Science Technology, the last three have been harrowing. Destocking and lower funding weighed on 2023-2024 revenue and a hostile DC environment of NIH budget cuts, tariffs, and drug pricing shook investor confidence in 2025. However, with policy issues dissipating, improved biopharma spend was evident with 3Q25 earnings (best in ~2 years) and large-caps DHR and TMO are leading a share price recovery. Data points in our LabBook signal more momentum in 2026, http://www.streetinsider.com/Analyst+Comments/KeyBanc+on+Life+Sciences+Tools+%26+Services%3A+%27We+Highlight+Our+Favored+2026+%22Tools%22+Stocks%27/25709383.html Mon, 08 Dec 2025 07:11:41 -0500 AVTR BDX BLFS CYRX DHR PPD RGEN RPID STVN TMO WAT WST XGN http://www.streetinsider.com/Analyst+Comments/KeyBanc+on+Life+Sciences+Tools+%26+Services%3A+%27We+Highlight+Our+Favored+2026+%22Tools%22+Stocks%27/25709383.html <p>KeyBanc analyst Paul Knight highlights favorite 2026 Life Sciences Tools & Services ideas from large to microcap.</p><p>The analyst commented: "Relative to a mostly predictable 20+ years in Life Science Technology, the last three have been harrowing. Destocking and lower funding weighed on 2023-2024 revenue and a hostile DC environment of NIH budget cuts, tariffs, and drug pricing shook investor confidence in 2025. However, with policy issues dissipating, improved biopharma spend was evident with 3Q25 earnings (best in ~2 years) and large-caps DHR and TMO are leading a share price recovery. Data points in our LabBook signal more momentum in 2026, http://www.streetinsider.com/Analyst+Comments/KeyBanc+on+Life+Sciences+Tools+%26+Services%3A+%27We+Highlight+Our+Favored+2026+%22Tools%22+Stocks%27/25709383.html Mon, 08 Dec 2025 07:11:41 -0500 AVTR BDX BLFS CYRX DHR PPD RGEN RPID STVN TMO WAT WST XGN http://www.streetinsider.com/Analyst+Comments/KeyBanc+on+Life+Sciences+Tools+%26+Services%3A+%27We+Highlight+Our+Favored+2026+%22Tools%22+Stocks%27/25709383.html <p>KeyBanc analyst Paul Knight highlights favorite 2026 Life Sciences Tools & Services ideas from large to microcap.</p><p>The analyst commented: "Relative to a mostly predictable 20+ years in Life Science Technology, the last three have been harrowing. Destocking and lower funding weighed on 2023-2024 revenue and a hostile DC environment of NIH budget cuts, tariffs, and drug pricing shook investor confidence in 2025. However, with policy issues dissipating, improved biopharma spend was evident with 3Q25 earnings (best in ~2 years) and large-caps DHR and TMO are leading a share price recovery. Data points in our LabBook signal more momentum in 2026, http://www.streetinsider.com/Analyst+Comments/KeyBanc+on+Life+Sciences+Tools+%26+Services%3A+%27We+Highlight+Our+Favored+2026+%22Tools%22+Stocks%27/25709383.html Mon, 08 Dec 2025 07:11:41 -0500 AVTR BDX BLFS CYRX DHR PPD RGEN RPID STVN TMO WAT WST XGN http://www.streetinsider.com/Analyst+Comments/KeyBanc+on+Life+Sciences+Tools+%26+Services%3A+%27We+Highlight+Our+Favored+2026+%22Tools%22+Stocks%27/25709383.html <p>KeyBanc analyst Paul Knight highlights favorite 2026 Life Sciences Tools & Services ideas from large to microcap.</p><p>The analyst commented: "Relative to a mostly predictable 20+ years in Life Science Technology, the last three have been harrowing. Destocking and lower funding weighed on 2023-2024 revenue and a hostile DC environment of NIH budget cuts, tariffs, and drug pricing shook investor confidence in 2025. However, with policy issues dissipating, improved biopharma spend was evident with 3Q25 earnings (best in ~2 years) and large-caps DHR and TMO are leading a share price recovery. Data points in our LabBook signal more momentum in 2026, http://www.streetinsider.com/Analyst+Comments/KeyBanc+on+Life+Sciences+Tools+%26+Services%3A+%27We+Highlight+Our+Favored+2026+%22Tools%22+Stocks%27/25709383.html Mon, 08 Dec 2025 07:11:41 -0500 AVTR BDX BLFS CYRX DHR PPD RGEN RPID STVN TMO WAT WST XGN http://www.streetinsider.com/Analyst+Comments/KeyBanc+on+Life+Sciences+Tools+%26+Services%3A+%27We+Highlight+Our+Favored+2026+%22Tools%22+Stocks%27/25709383.html <p>KeyBanc analyst Paul Knight highlights favorite 2026 Life Sciences Tools & Services ideas from large to microcap.</p><p>The analyst commented: "Relative to a mostly predictable 20+ years in Life Science Technology, the last three have been harrowing. Destocking and lower funding weighed on 2023-2024 revenue and a hostile DC environment of NIH budget cuts, tariffs, and drug pricing shook investor confidence in 2025. However, with policy issues dissipating, improved biopharma spend was evident with 3Q25 earnings (best in ~2 years) and large-caps DHR and TMO are leading a share price recovery. Data points in our LabBook signal more momentum in 2026, http://www.streetinsider.com/Analyst+Comments/KeyBanc+on+Life+Sciences+Tools+%26+Services%3A+%27We+Highlight+Our+Favored+2026+%22Tools%22+Stocks%27/25709383.html Mon, 08 Dec 2025 07:11:41 -0500 AVTR BDX BLFS CYRX DHR PPD RGEN RPID STVN TMO WAT WST XGN http://www.streetinsider.com/Analyst+Comments/KeyBanc+on+Life+Sciences+Tools+%26+Services%3A+%27We+Highlight+Our+Favored+2026+%22Tools%22+Stocks%27/25709383.html <p>KeyBanc analyst Paul Knight highlights favorite 2026 Life Sciences Tools & Services ideas from large to microcap.</p><p>The analyst commented: "Relative to a mostly predictable 20+ years in Life Science Technology, the last three have been harrowing. Destocking and lower funding weighed on 2023-2024 revenue and a hostile DC environment of NIH budget cuts, tariffs, and drug pricing shook investor confidence in 2025. However, with policy issues dissipating, improved biopharma spend was evident with 3Q25 earnings (best in ~2 years) and large-caps DHR and TMO are leading a share price recovery. Data points in our LabBook signal more momentum in 2026, http://www.streetinsider.com/Analyst+Comments/KeyBanc+on+Life+Sciences+Tools+%26+Services%3A+%27We+Highlight+Our+Favored+2026+%22Tools%22+Stocks%27/25709383.html Mon, 08 Dec 2025 07:11:41 -0500 AVTR BDX BLFS CYRX DHR PPD RGEN RPID STVN TMO WAT WST XGN http://www.streetinsider.com/Analyst+Comments/KeyBanc+on+Life+Sciences+Tools+%26+Services%3A+%27We+Highlight+Our+Favored+2026+%22Tools%22+Stocks%27/25709383.html <p>KeyBanc analyst Paul Knight highlights favorite 2026 Life Sciences Tools & Services ideas from large to microcap.</p><p>The analyst commented: "Relative to a mostly predictable 20+ years in Life Science Technology, the last three have been harrowing. Destocking and lower funding weighed on 2023-2024 revenue and a hostile DC environment of NIH budget cuts, tariffs, and drug pricing shook investor confidence in 2025. However, with policy issues dissipating, improved biopharma spend was evident with 3Q25 earnings (best in ~2 years) and large-caps DHR and TMO are leading a share price recovery. Data points in our LabBook signal more momentum in 2026, http://www.streetinsider.com/Analyst+Comments/KeyBanc+on+Life+Sciences+Tools+%26+Services%3A+%27We+Highlight+Our+Favored+2026+%22Tools%22+Stocks%27/25709383.html Mon, 08 Dec 2025 07:11:41 -0500 AVTR BDX BLFS CYRX DHR PPD RGEN RPID STVN TMO WAT WST XGN http://www.streetinsider.com/Analyst+Comments/KeyBanc+on+Life+Sciences+Tools+%26+Services%3A+%27We+Highlight+Our+Favored+2026+%22Tools%22+Stocks%27/25709383.html <p>KeyBanc analyst Paul Knight highlights favorite 2026 Life Sciences Tools & Services ideas from large to microcap.</p><p>The analyst commented: "Relative to a mostly predictable 20+ years in Life Science Technology, the last three have been harrowing. Destocking and lower funding weighed on 2023-2024 revenue and a hostile DC environment of NIH budget cuts, tariffs, and drug pricing shook investor confidence in 2025. However, with policy issues dissipating, improved biopharma spend was evident with 3Q25 earnings (best in ~2 years) and large-caps DHR and TMO are leading a share price recovery. Data points in our LabBook signal more momentum in 2026, http://www.streetinsider.com/Analyst+Comments/KeyBanc+on+Life+Sciences+Tools+%26+Services%3A+%27We+Highlight+Our+Favored+2026+%22Tools%22+Stocks%27/25709383.html Mon, 08 Dec 2025 07:11:41 -0500 AVTR BDX BLFS CYRX DHR PPD RGEN RPID STVN TMO WAT WST XGN http://www.streetinsider.com/Analyst+Comments/KeyBanc+on+Life+Sciences+Tools+%26+Services%3A+%27We+Highlight+Our+Favored+2026+%22Tools%22+Stocks%27/25709383.html <p>KeyBanc analyst Paul Knight highlights favorite 2026 Life Sciences Tools & Services ideas from large to microcap.</p><p>The analyst commented: "Relative to a mostly predictable 20+ years in Life Science Technology, the last three have been harrowing. Destocking and lower funding weighed on 2023-2024 revenue and a hostile DC environment of NIH budget cuts, tariffs, and drug pricing shook investor confidence in 2025. However, with policy issues dissipating, improved biopharma spend was evident with 3Q25 earnings (best in ~2 years) and large-caps DHR and TMO are leading a share price recovery. Data points in our LabBook signal more momentum in 2026, http://www.streetinsider.com/Analyst+Comments/KeyBanc+on+Life+Sciences+Tools+%26+Services%3A+%27We+Highlight+Our+Favored+2026+%22Tools%22+Stocks%27/25709383.html Mon, 08 Dec 2025 07:11:41 -0500 AVTR BDX BLFS CYRX DHR PPD RGEN RPID STVN TMO WAT WST XGN http://www.streetinsider.com/Investing/Sage+stock+slides+as+RBC+cuts+rating+to+Sell+on+trial+results+concerns/23803673.html <p>Investing.com -- RBC Capital Markets cut its rating on SAGE Therapeutics Inc (NASDAQ:SAGE) from Sector Perform to Underperform (Sell), due to concerns about the potential outcomes of the company's drug trials. The investment bank also lowered its price target to $4 from $10.</p> <p>Shares in the biopharmaceutical company fell nearly 8% in premarket trading Friday.</p> <p>The downgrade is primarily based on the analysis of Sage's experimental drug dalzanemdor and its upcoming phase II trial results for Huntington's and Alzheimer's diseases, expected in the fourth quarter of 2024.</p> <p>RBC expressed doubt about the drug showing clear, clinically meaningful effects in these conditions.</p> <p>“Without success for http://www.streetinsider.com/Investing/Sage+stock+slides+as+RBC+cuts+rating+to+Sell+on+trial+results+concerns/23803673.html Fri, 04 Oct 2024 09:28:37 -0500 PPD SAGE http://www.streetinsider.com/Investing/Sage+stock+slides+as+RBC+cuts+rating+to+Sell+on+trial+results+concerns/23803673.html <p>Investing.com -- RBC Capital Markets cut its rating on SAGE Therapeutics Inc (NASDAQ:SAGE) from Sector Perform to Underperform (Sell), due to concerns about the potential outcomes of the company's drug trials. The investment bank also lowered its price target to $4 from $10.</p> <p>Shares in the biopharmaceutical company fell nearly 8% in premarket trading Friday.</p> <p>The downgrade is primarily based on the analysis of Sage's experimental drug dalzanemdor and its upcoming phase II trial results for Huntington's and Alzheimer's diseases, expected in the fourth quarter of 2024.</p> <p>RBC expressed doubt about the drug showing clear, clinically meaningful effects in these conditions.</p> <p>“Without success for http://www.streetinsider.com/Investing/Sage+stock+slides+as+RBC+cuts+rating+to+Sell+on+trial+results+concerns/23803673.html Fri, 04 Oct 2024 09:28:37 -0500 PPD SAGE http://www.streetinsider.com/Downgrades/Sage+stock+slides+as+RBC+cuts+rating+to+Sell+on+trial+results+concerns/23803673.html <p>Investing.com -- RBC Capital Markets cut its rating on SAGE Therapeutics Inc (NASDAQ:SAGE) from Sector Perform to Underperform (Sell), due to concerns about the potential outcomes of the company's drug trials. The investment bank also lowered its price target to $4 from $10.</p> <p>Shares in the biopharmaceutical company fell nearly 8% in premarket trading Friday.</p> <p>The downgrade is primarily based on the analysis of Sage's experimental drug dalzanemdor and its upcoming phase II trial results for Huntington's and Alzheimer's diseases, expected in the fourth quarter of 2024.</p> <p>RBC expressed doubt about the drug showing clear, clinically meaningful effects in these conditions.</p> <p>“Without success for http://www.streetinsider.com/Downgrades/Sage+stock+slides+as+RBC+cuts+rating+to+Sell+on+trial+results+concerns/23803673.html Fri, 04 Oct 2024 09:28:37 -0500 PPD SAGE http://www.streetinsider.com/Downgrades/Sage+stock+slides+as+RBC+cuts+rating+to+Sell+on+trial+results+concerns/23803673.html <p>Investing.com -- RBC Capital Markets cut its rating on SAGE Therapeutics Inc (NASDAQ:SAGE) from Sector Perform to Underperform (Sell), due to concerns about the potential outcomes of the company's drug trials. The investment bank also lowered its price target to $4 from $10.</p> <p>Shares in the biopharmaceutical company fell nearly 8% in premarket trading Friday.</p> <p>The downgrade is primarily based on the analysis of Sage's experimental drug dalzanemdor and its upcoming phase II trial results for Huntington's and Alzheimer's diseases, expected in the fourth quarter of 2024.</p> <p>RBC expressed doubt about the drug showing clear, clinically meaningful effects in these conditions.</p> <p>“Without success for http://www.streetinsider.com/Downgrades/Sage+stock+slides+as+RBC+cuts+rating+to+Sell+on+trial+results+concerns/23803673.html Fri, 04 Oct 2024 09:28:37 -0500 PPD SAGE http://www.streetinsider.com/Press+Releases/Saama+Appoints+Scott+Rogers+as+Company%E2%80%99s+Chief+Financial+Officer/19543899.html si-local-file:///var/storage/newsbody/2022/0202/19543899.html http://www.streetinsider.com/Press+Releases/Saama+Appoints+Scott+Rogers+as+Company%E2%80%99s+Chief+Financial+Officer/19543899.html Wed, 02 Feb 2022 08:00:00 -0500 A.06136199 A.06554554 A.31007879 A.40132879 PPD http://www.streetinsider.com/Press+Releases/Saama+Appoints+Scott+Rogers+as+Company%E2%80%99s+Chief+Financial+Officer/19543899.html si-local-file:///var/storage/newsbody/2022/0202/19543899.html http://www.streetinsider.com/Press+Releases/Saama+Appoints+Scott+Rogers+as+Company%E2%80%99s+Chief+Financial+Officer/19543899.html Wed, 02 Feb 2022 08:00:00 -0500 A.06136199 A.06554554 A.31007879 A.40132879 PPD http://www.streetinsider.com/Press+Releases/Saama+Appoints+Scott+Rogers+as+Company%E2%80%99s+Chief+Financial+Officer/19543899.html si-local-file:///var/storage/newsbody/2022/0202/19543899.html http://www.streetinsider.com/Press+Releases/Saama+Appoints+Scott+Rogers+as+Company%E2%80%99s+Chief+Financial+Officer/19543899.html Wed, 02 Feb 2022 08:00:00 -0500 A.06136199 A.06554554 A.31007879 A.40132879 PPD http://www.streetinsider.com/Press+Releases/Saama+Appoints+Scott+Rogers+as+Company%E2%80%99s+Chief+Financial+Officer/19543899.html si-local-file:///var/storage/newsbody/2022/0202/19543899.html http://www.streetinsider.com/Press+Releases/Saama+Appoints+Scott+Rogers+as+Company%E2%80%99s+Chief+Financial+Officer/19543899.html Wed, 02 Feb 2022 08:00:00 -0500 A.06136199 A.06554554 A.31007879 A.40132879 PPD http://www.streetinsider.com/Press+Releases/Saama+Appoints+Scott+Rogers+as+Company%E2%80%99s+Chief+Financial+Officer/19543899.html si-local-file:///var/storage/newsbody/2022/0202/19543899.html http://www.streetinsider.com/Press+Releases/Saama+Appoints+Scott+Rogers+as+Company%E2%80%99s+Chief+Financial+Officer/19543899.html Wed, 02 Feb 2022 08:00:00 -0500 A.06136199 A.06554554 A.31007879 A.40132879 PPD http://www.streetinsider.com/Business+Wire/Saama+Appoints+Scott+Rogers+as+Company%E2%80%99s+Chief+Financial+Officer/19543899.html si-local-file:///var/storage/newsbody/2022/0202/19543899.html http://www.streetinsider.com/Business+Wire/Saama+Appoints+Scott+Rogers+as+Company%E2%80%99s+Chief+Financial+Officer/19543899.html Wed, 02 Feb 2022 08:00:00 -0500 A.06136199 A.06554554 A.31007879 A.40132879 PPD http://www.streetinsider.com/Business+Wire/Saama+Appoints+Scott+Rogers+as+Company%E2%80%99s+Chief+Financial+Officer/19543899.html si-local-file:///var/storage/newsbody/2022/0202/19543899.html http://www.streetinsider.com/Business+Wire/Saama+Appoints+Scott+Rogers+as+Company%E2%80%99s+Chief+Financial+Officer/19543899.html Wed, 02 Feb 2022 08:00:00 -0500 A.06136199 A.06554554 A.31007879 A.40132879 PPD http://www.streetinsider.com/Business+Wire/Saama+Appoints+Scott+Rogers+as+Company%E2%80%99s+Chief+Financial+Officer/19543899.html si-local-file:///var/storage/newsbody/2022/0202/19543899.html http://www.streetinsider.com/Business+Wire/Saama+Appoints+Scott+Rogers+as+Company%E2%80%99s+Chief+Financial+Officer/19543899.html Wed, 02 Feb 2022 08:00:00 -0500 A.06136199 A.06554554 A.31007879 A.40132879 PPD